Other Streetwise Reports
The Gold Report The Energy Report The Life Sciences Report The Metals ReportMore Experts
"NEO is a small but focused diagnostic company with numerous competitive advantages." (4/4/13) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng More >
"I believe the monoclonal antibody technology that SYN is working on for pertussis is especially interesting." (3/28/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Keith Markey More >
"ATHX has one of the best manufacturing processes in allogeneic cell therapy I've ever seen." (3/14/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >
Sector Experts
Subscribe to
Streetwise Reports
Companies Commented On
- Big Sky Petroleum Corp.
- biOasis Technologies Inc.
- DNI Metals Inc.
- Energy Fuels Inc.
- Molycorp Inc.
- Oncolytics Biotech Inc.
- Resverlogix Corp.
- Ur-Energy Inc.
- Uranerz Energy Corp.
- Uranium Energy Corp.
Jim Letourneau
Big Picture Speculator
http://www.jimletourneau.com
Jim Letourneau is the founder and editor of the Big Picture Speculator and is a geologist living in Calgary, Alberta. He is an early-stage investor in energy, metals, biotech and technology companies. He speaks at investment conferences across North America.
Recent Interviews
Unconventional: Jim Letourneau's Investment Taste (4/25/13) Whether the topic is peak oil, climate change or commodity bull markets, Jim Letourneau tends to take the contrarian position. He's an unapologetic advocate of oil sands development and a shrewd analyst of the companies large and small that are active both in the Alberta oil sands and in the U.S. oil patch. In this interview with The Energy Report, he shares his insights into one of Alberta's largest oil sands players and one of its newest and smallest, as well as a well-positioned startup in the Texas Midland basin and northwestern Montana's Williston basin.
Anything for a Buck: Jim Letourneau Looks to Canadian Biotech for Opportunity (1/17/13) To avoid some of the "dysfunctional excess" of the energy and mining sectors, Jim Letourneau, self-described contrarian and founder and editor of the Big Picture Speculator, turns to investing in biotech. His focus is on Canadian companies, which he believes perform on a par with companies in the United States. In this interview with The Life Sciences Report, Letourneau describes what he looks for in a biotech investment and names some of his favorite companies.
Recent Quotes
"I think everyone is expecting BSP's share value to grow." (4/25/13) Big Sky Petroleum Corp. - The Energy Report Interview with Jim Letourneau More >
"URE just closed a $5.1M transaction that provides upfront cash in return for future uranium deliveries." (4/25/13) Ur-Energy Inc. - The Energy Report Interview with Jim Letourneau More >
"Big pharma is interested in BTI." (1/17/13) biOasis Technologies Inc. - The Life Sciences Report Interview with Jim Letourneau More >
"RVX is busily building an intellectual property fence around the proteins it has been working on." (1/17/13) Resverlogix Corp. - The Life Sciences Report Interview with Jim Letourneau More >
"ONCY is a good example of a company with good prospects in 2013." (1/17/13) Oncolytics Biotech Inc. - The Life Sciences Report Interview with Jim Letourneau More >
"UEC is currently producing in Texas, with more projects coming on-line." (4/3/12) Uranium Energy Corp. - The Energy Report Interview with Jim Letourneau More >
"URZ should start producing 600–800 Klb uranium/year very shortly." (4/3/12) Uranerz Energy Corp. - The Energy Report Interview with Jim Letourneau More >
"URE is on track to become a producer very soon." (4/3/12) Ur-Energy Inc. - The Energy Report Interview with Jim Letourneau More >
Notable Quotes
"I think GALE has a good shot on its phase 3 NeuVax trial." (5/23/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Echo He More >
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
The Life Sciences Report